The next generation biopharmaceuticals

Phase 2 LINNAEA Study Presented at EURETINA

2021-09-09

Phase 2 LINNEA Study Presented at EURETINA

Solna, Sweden, September 9, 2021. Affibody AB (“Affibody”) today announced that Professor Quan Dong Nguyen, Principal Coordinating Investigator of the LINNAEA Study, that will investigate izokibep (ABY-035) in uveitis, will present at the European Society of Retina Specialists virtual conference EURETINA 2021.

Professor Quan Dong Nguyen, MD, MSc, FARVO, Principal Coordinating Investigator of the LINNAEA Study, and Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine, USA, will give a presentation on the topic of “New biological treatments of posterior uveitis” at the EURETINA Uveitis Endophthalmitis session Thursday, 9th September, 2021 at 16:45 CEST.

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)